Atrium Therapeutics Ownership | Who Owns Atrium Therapeutics?

Overview Forecast RevenueFinancials Chart

Atrium Therapeutics Ownership Summary

Atrium Therapeutics is owned by 83.59% institutional investors, 4.27% insiders, and 12.14% retail investors. Vanguard group is the largest institutional shareholder, holding 9.90% of RNA shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 4.27% of its assets in Atrium Therapeutics shares.

RNA Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Atrium Therapeutics	83.59%	4.27%	12.14%
Sector	Healthcare Stocks	50.62%	12.41%	36.97%
Industry	Biotech Stocks	49.15%	12.15%	38.70%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vanguard group	13.65M	9.90%	$984.52M
Blackrock	8.62M	9.89%	$352.23M
Rtw investments, lp	11.37M	8.77%	$495.51M
Sessa capital im	1.50M	8.77%	$20.18M
Price t rowe associates inc /md/	1.47M	8.61%	$19.81M
Blackrock funding, inc. /de	1.45M	8.46%	$19.47M
Vanguard capital management	730.83K	4.27%	$9.83M
Crcm lp	583.25K	3.41%	$7.84M
Tig advisors	561.53K	3.28%	$7.55M
Geode capital management	386.93K	2.26%	$5.21M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Rtw investments, lp	11.37M	6.11%	$495.51M
Crcm lp	583.25K	5.44%	$7.84M
Bioimpact capital	760.02K	5.42%	$33.11M
Boxer capital	1.73M	3.72%	$70.56M
Catalio capital management, lp	263.26K	2.12%	$11.47M
Arbiter partners capital management	261.29K	1.85%	$3.51M
Ecor1 capital	765.00K	1.60%	$33.33M
Stempoint capital lp	114.05K	1.00%	$4.97M
Trium capital llp	113.28K	0.94%	$1.52M
Eversept partners, lp	302.91K	0.91%	$13.20M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	8.62M	0.01%	2.46M
Rtw investments, lp	11.37M	6.11%	1.75M
Polar capital	2.80M	0.59%	1.03M
Sessa capital im	1.50M	0.34%	948.61K
Suvretta capital management	750.00K	0.84%	750.00K

Top Sellers

Holder	Shares	% Assets	Change
Janus henderson group	-	-	-6.94M
Avoro capital advisors	-	-	-5.46M
Cowen and company	-	-	-5.13M
Hbk investments l p	-	-	-4.37M
Glazer capital	-	-	-2.47M

New Positions

Holder	Shares	% Assets	Change	Value
Suvretta capital management	750.00K	0.84%	750.00K	$32.68M
Artal group	655.55K	0.68%	655.55K	$26.78M
Baker bros. advisors lp	625.00K	0.20%	625.00K	$27.23M
Crcm lp	583.25K	5.44%	583.25K	$7.84M
Braidwell lp	331.91K	0.43%	331.91K	$14.46M

Sold Out

Holder	Change
Root financial partners	-1.00
Dinuzzo private wealth	-1.00
Bare financial services	-1.00
American capital advisory	-1.00
Hfm investment advisors	-1.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	156	-6.59%	14,298,610	-3.71%	83	1.11%	85	117.95%	36	-69.75%
Mar 31, 2026	53	-85.40%	1,674,179	-98.81%	9	0.00%	13	-94.20%	38	-56.32%
Dec 31, 2025	226	-23.39%	67,965,698	-57.78%	49	0.32%	133	-34.48%	57	1.79%
Sep 30, 2025	164	-23.72%	64,667,711	-52.44%	49	0.45%	117	6.36%	37	-51.32%
Jun 30, 2025	214	-6.96%	135,949,346	3.28%	104	1.01%	109	-16.15%	76	16.92%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Growth Compy Commingled Pl S	5.49M	4.27%	109.14K
Fidelity Growth Compy Commingled Pl O	4.86M	4.11%	-69.00K
US Small-Cap Growth II Equity Comp	3.95M	3.28%	-484.27K
Fidelity Growth Company Fund	3.99M	3.10%	77.74K
Vanguard US Total Market Shares ETF	3.53M	2.93%	3.12K
Vanguard Total Stock Mkt Idx Inv	4.54M	2.92%	10.44K
T. Rowe Price New Horizons	3.54M	2.75%	-414.46K
Vanguard Health Care Inv	2.83M	2.35%	-196.40K
Vanguard Small Cap Index	3.25M	2.09%	3.86K
iShares Russell 2000 ETF	2.77M	1.79%	2.77M

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jan 21, 2026	Hughes Steven George	Chief Medical Officer	Sell	$208.51K
Jan 21, 2026	Hughes Steven George	Chief Medical Officer	Sell	$146.13K
Jan 21, 2026	Boyce Sarah	President and CEO	Sell	$463.25K
Jan 21, 2026	Boyce Sarah	President and CEO	Sell	$579.09K
Jan 21, 2026	Flanagan W. Michael	Chief Scientific Officer	Sell	$288.06K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	18
2025 Q4	-	3
2025 Q3	-	23
2025 Q2	-	5
2025 Q1	-	23

RNA Ownership FAQ

Who Owns Atrium Therapeutics?

Atrium Therapeutics shareholders are primarily institutional investors at 83.59%, followed by 4.27% insiders and 12.14% retail investors. The average institutional ownership in Atrium Therapeutics's industry, Biotech Stocks , is 49.15%, which Atrium Therapeutics exceeds.

Who owns the most shares of Atrium Therapeutics?

Atrium Therapeutics’s largest shareholders are Vanguard group (13.65M shares, 9.90%), Blackrock (8.62M shares, 9.89%), and Rtw investments, lp (11.37M shares, 8.77%). Together, they hold 28.56% of Atrium Therapeutics’s total shares outstanding.

Does Blackrock own Atrium Therapeutics?

Yes, BlackRock owns 9.89% of Atrium Therapeutics, totaling 8.62M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 352.23M$. In the last quarter, BlackRock increased its holdings by 2.46M shares, a 39.84% change.

Who is Atrium Therapeutics’s biggest shareholder by percentage of total assets invested?

Rtw investments, lp is Atrium Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.11% of its assets in 11.37M Atrium Therapeutics shares, valued at 495.51M$.

Who is the top mutual fund holder of Atrium Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Atrium Therapeutics shares, with 4.27% of its total shares outstanding invested in 5.49M Atrium Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools